Cargando…

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections

Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallerani, Altea, Gatti, Milo, Bedini, Andrea, Casolari, Stefania, Orlando, Gabriella, Puzzolante, Cinzia, Franceschini, Erica, Menozzi, Marianna, Santoro, Antonella, Barp, Nicole, Volpi, Sara, Soffritti, Alessandra, Pea, Federico, Mussini, Cristina, Meschiari, Marianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669433/ https://www.ncbi.nlm.nih.gov/pubmed/37998841 http://dx.doi.org/10.3390/antibiotics12111639

Ejemplares similares

Risk factors for nosocomial rectal colonization with carbapenem-resistant Acinetobacter baumannii in hospital: a matched case–control study
por: Meschiari, Marianna, et al.
Publicado: (2021)

The Impact of COVID-19 on UNAIDS 90–90–90 Targets: Calls for New HIV Care Models
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period
por: Franceschini, E., et al.
Publicado: (2020)

Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?
por: Medioli, Filippo, et al.
Publicado: (2022)

Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients
por: Alfano, Gaetano, et al.
Publicado: (2021)

Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19
por: Alfano, Gaetano, et al.
Publicado: (2021)

Granulicatella adiacens and Abiotrophia defectiva Native Vertebral Osteomyelitis: Three Cases and Literature Review of Clinical Characteristics and Treatment Approach
por: Puzzolante, Cinzia, et al.
Publicado: (2019)

First Human Case of Tick-Borne Encephalitis in Non-Endemic Region in Italy: A Case Report
por: Barp, Nicole, et al.
Publicado: (2022)

1979. Five-Year Impact of an Antimicrobial Stewardship Program on Nosocomial Candidemia: An Interrupted Time-Series Analysis Study
por: Bedini, Andrea, et al.
Publicado: (2019)

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
por: Meschiari, Marianna, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015–2021)
por: Meschiari, Marianna, et al.
Publicado: (2022)

Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature
por: Bacca, Erica, et al.
Publicado: (2021)

Hypokalemia in Patients with COVID-19
por: Alfano, Gaetano, et al.
Publicado: (2021)

The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study
por: Milic, Jovana, et al.
Publicado: (2021)

Tocilizumab in patients with severe COVID-19: a retrospective cohort study
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
por: Burastero, Giulia Jole, et al.
Publicado: (2022)

Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria
por: Santoro, Antonella, et al.
Publicado: (2020)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
por: Gatti, Milo, et al.
Publicado: (2021)

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
por: Meschiari, Marianna, et al.
Publicado: (2020)

Clinical and Microbiological Characteristics of Visceral Leishmaniasis Outbreak in a Northern Italian Nonendemic Area: A Retrospective Observational Study
por: Franceschini, E., et al.
Publicado: (2016)

Pneumocystosis as a Complication of H1N1 Influenza A Infection in an HIV-Positive Patient on Effective cART
por: Franconi, Iacopo, et al.
Publicado: (2019)

Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study
por: Franceschini, Erica, et al.
Publicado: (2021)

A Fatal Case of Pseudomonas aeruginosa Community-Acquired Pneumonia in an Immunocompetent Patient: Clinical and Molecular Characterization and Literature Review
por: Barp, Nicole, et al.
Publicado: (2023)

2443. Impact of Antimicrobial Stewardship on the Incidence of Carbapenem-Resistant Pseudomonas aeruginosa: A Nonlinear Time-Series Analysis Approach to Identify Carpapenem Thresholds
por: Meschiari, Marianna, et al.
Publicado: (2019)

Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator
por: Mussini, Cristina, et al.
Publicado: (2021)

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
por: Barone, Rossella, et al.
Publicado: (2023)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency
por: Ferrari, Davide, et al.
Publicado: (2020)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
por: Buzón-Martín, Luis, et al.
Publicado: (2021)

First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy
por: Meschiari, Marianna, et al.
Publicado: (2022)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) Pseudomonas aeruginosa: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
por: Meschiari, Marianna, et al.
Publicado: (2021)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
por: Ruiz-Sancho, Andrés, et al.
Publicado: (2023)

CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk
por: Menozzi, Marianna, et al.
Publicado: (2014)

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
por: Alteri, Claudia, et al.
Publicado: (2022)

Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin
por: Söderquist, Bo, et al.
Publicado: (2023)

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
por: Lange, Anna, et al.
Publicado: (2023)

Acid base disorders in patients with COVID-19
por: Alfano, Gaetano, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
por: Franceschini, Erica, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_65t8qmo6jq3jq6ngbo5vb34tlf